Psychoactive fungi

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica

Retrieved on: 
Tuesday, February 9, 2021

TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce the official opening of the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica.

Key Points: 
  • TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce the official opening of the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica.
  • The research facility, which is opening as part of Field Trips previously announced strategic partnership with the University of West Indies, is the worlds first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.
  • The Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi will officially open with a Grand Opening Ceremony on Tuesday, February 9th at 2PM EST.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.

REPEAT - Pure Extracts Announces Submission for Class 1 Natural Product Number (NPN)

Retrieved on: 
Wednesday, February 3, 2021

This has allowed Pure Extracts to submit a Class 1 Natural Product Number (NPN) application for a functional mushroom product, which the Company expects will be the first of several NPN applications that it submits in 2021.

Key Points: 
  • This has allowed Pure Extracts to submit a Class 1 Natural Product Number (NPN) application for a functional mushroom product, which the Company expects will be the first of several NPN applications that it submits in 2021.
  • Pure Extracts plans to sell functional mushroom wellness products through its newly incorporated, wholly owned subsidiary, Pure Mushrooms Corp.
  • Sales will take place direct-to-consumer through an e-Commerce portal that the Company is establishing, and the brand will be called Pure Mushrooms.
  • Pure Extracts CEO, Ben Nikolaevsky, remarked, The functional mushroom wellness sector is experiencing tremendous growth and consumer awareness, we remain very excited about our new Pure Mushrooms brand.

COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy

Retrieved on: 
Wednesday, February 3, 2021

The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy.

Key Points: 
  • The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy.
  • In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists.
  • We will continue to evolve our training programme as we progress COMP360 psilocybin therapy through clinical trials.
  • We hope that this first step encourages collaboration among therapist training providers, as we work towards bringing psilocybin therapy to all who might benefit.

Pure Extracts Announces Submission for Class 1 Natural Product Number (NPN)

Retrieved on: 
Wednesday, February 3, 2021

This has allowed Pure Extracts to submit a Class 1 Natural Product Number (NPN) application for a functional mushroom product, which the Company expects will be the first of several NPN applications that it submits in 2021.

Key Points: 
  • This has allowed Pure Extracts to submit a Class 1 Natural Product Number (NPN) application for a functional mushroom product, which the Company expects will be the first of several NPN applications that it submits in 2021.
  • Pure Extracts plans to sell functional mushroom wellness products through its newly incorporated, wholly owned subsidiary, Pure Mushrooms Corp.
  • Sales will take place direct-to-consumer through an e-Commerce portal that the Company is establishing, and the brand will be called Pure Mushrooms.
  • Pure Extracts CEO, Ben Nikolaevsky, remarked, The functional mushroom wellness sector is experiencing tremendous growth and consumer awareness, we remain very excited about our new Pure Mushrooms brand.

Allied Completes Acquisition of Pacific Sun Fungi: A Leader in the Psilocybin Space

Retrieved on: 
Tuesday, February 2, 2021

Allied has now completed the acquisition of Pacific Sun Fungi which is now a 100% wholly owned subsidiary of Allied.

Key Points: 
  • Allied has now completed the acquisition of Pacific Sun Fungi which is now a 100% wholly owned subsidiary of Allied.
  • Pacific Sun has many products ready for clinical intake that consist of both novel functional mushroom formulations including psilocybin and additional medical mushrooms.
  • Allied will be researching, and intends to bring to market, a 100mg psilocybin formulation, a 250mg formulation.
  • The acquisition of Pacific Sun Fungi has advanced Allied into the broader mental health market encompassing both pharmaceutical and natural health products.

Global Wellness Strategies and EntheoTech Bioscience Sign Letter of Intent; EntheoTech Focused on Functional & Psilocybin Products

Retrieved on: 
Wednesday, January 27, 2021

EntheoTech is a Canadian bioscience company focused on the research and development of products, and protocols to promote brain health, performance optimization, and global wellness, using psychoactive substances such as psilocybin, medicinal mushrooms, and other natural products.

Key Points: 
  • EntheoTech is a Canadian bioscience company focused on the research and development of products, and protocols to promote brain health, performance optimization, and global wellness, using psychoactive substances such as psilocybin, medicinal mushrooms, and other natural products.
  • EntheoTech will also be launching a direct-to-consumer line of functional mushroom products using unique formulations and manufacturing methods to increase bioavailability and efficacy.
  • Global agrees to purchase 19.9% of the rights to the products and licenses from ET at a valuation to be determined during the due diligence period.
  • Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products.

Minerco Inc. the Magic Mushroom Company Receives 1B Valuation Pre-Money Business Valuation from EQUIDAM

Retrieved on: 
Tuesday, January 19, 2021

Minerco's Valuation report list IPEV at 297M, LTG AT 193M and DCF TV AT 1B.

Key Points: 
  • Minerco's Valuation report list IPEV at 297M, LTG AT 193M and DCF TV AT 1B.
  • Minerco's will use Valuation as an indicator to the business opportunity in this emerging industry.
  • In addition, Minerco intends raise capital to do the following:
    Acquire and retire Toxic Debt from balance sheet.
  • The Magic Mushroom Company (OTC Pink: MINE) is emerging as the world's first publicly traded company focused on the research, production and distribution of psilocybin mushroom.

Minerco Inc the Magic Mushroom Company Appoints Health Care Consultant Paul Hoonjan as President

Retrieved on: 
Monday, January 11, 2021

Oakland, California--(Newsfile Corp. - January 11, 2021) - The Magic Mushroom Company (OTCP Pink: MINE) specializing in growing, research, production and distribution of psilocybin mushrooms, announced today that Paul Hoonjan has been appointed as its new President.

Key Points: 
  • Oakland, California--(Newsfile Corp. - January 11, 2021) - The Magic Mushroom Company (OTCP Pink: MINE) specializing in growing, research, production and distribution of psilocybin mushrooms, announced today that Paul Hoonjan has been appointed as its new President.
  • Hoonjan brings extensive experience, notably in the development and management of strategic opportunities, corporate alliances and bringing therapeutic products to market.
  • "For almost 6 years, Hoonjan has overseen Cannabis and Mushroom development in Runaway Bay, Jamaica managing international client base.
  • Hoonjan's expertise in shipping, contracting, negotiating, labor development, and building supply lines will reinforce Minerco's leadership in the emerging market.

Further Research into Psilocybin Opens New Doors for Treatment

Retrieved on: 
Thursday, January 7, 2021

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.

Key Points: 
  • Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,' said Dr. Polito.
  • Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University.

Further Research into Psilocybin Opens New Doors for Treatment

Retrieved on: 
Thursday, January 7, 2021

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.

Key Points: 
  • Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,' said Dr. Polito.
  • Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University.